Market Overview

Why Jefferies Upgraded Johnson & Johnson


On CNBC's "Power Lunch", Jefferies analyst Jeffrey Holford spoke about his upgrade of Johnson & Johnson (NYSE: JNJ).

He upgraded the stock to Buy and he increased its price target to $157 from $145. Holford sees the acquisition of Actelion as important and he thinks it's going to have a faster impact because Johnson & Johnson isn't taking all of its R&D infrastructure. The biggest driver of his Buy rating are the products that are already in the company, especially the oncology division.

Holford added that Talcum powder lawsuits shouldn't have a major impact on the company, because the big studies show no connection to cancer. The company has a strong balance sheet and it can deal with significant liabilities. He also thinks Johnson & Johnson would be interested in buying Pfizer's (NYSE: PFE) consumer health business.

Latest Ratings for JNJ

Apr 2020BarclaysMaintainsOverweight
Apr 2020Morgan StanleyMaintainsOverweight
Apr 2020UBSDowngradesBuyNeutral

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings


Related Articles (JNJ)

View Comments and Join the Discussion!

Posted-In: CNBC Jefferies Jeffrey HolfordAnalyst Color Upgrades Price Target Analyst Ratings Media

Latest Ratings

ETNB of A SecuritiesDowngrades
HUYAB of A SecuritiesReiterates23.0
BABANomura InstinetMaintains249.0
PDDB of A SecuritiesReiterates71.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at